Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353989 | 0.93 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL28375990 | 0.89 | CYP1A2 (0.60) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14353793 | 0.88 | ALDH1A1 (0.52) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14354161 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14354162 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14353799 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14353676 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL14354309 | 0.82 | HSD17B10 (0.62) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL16050548 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP1A2HPGDTHRB | |
| SCHEMBL3415 | 0.79 | ALDH1A1 (0.53) | ALDH1A1HSD17B10CYP1A2HPGDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105949432-B | A kind of modified gangue-rigid polyurethane foam compound insulating material | 南京理工大学 | 2018-08-17 | — | — | CN | claimed |
| US-20020034657-A1 | Organic electroluminescence device | NEC CORPORATION. | 2002-03-21 | — | — | US | claimed |
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| EP-3187225-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3858909-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3372281-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112839988-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2021-05-25 | — | — | CN | disclosed |
| EP-3196201-B1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006116764-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20020034657-A1 | Organic electroluminescence device | NEC CORPORATION. | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | ALDH1A1 418/4885HSD17B10 2403/4885CYP1A2 636/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | ALDH1A1 3160/4885HSD17B10 838/4885CYP1A2 434/4885 |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | NOC2L, RIF1, NAP1L1 | ALDH1A1 2699/4885HSD17B10 3823/4885CYP1A2 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.